Developing Non-Traditional Antibiotics

Explore the potential of non-traditional antibiotics in combating multidrug-resistant organisms in this 42-minute talk by Dr. John Rex, Chief Medical Officer at F2G Ltd. and Editor-in-Chief of AMR.solutions. Delve into the definition, clinical efficacy, and regulatory pathways for approval of these novel therapeutic strategies. Gain insights on augmenting features, patient-reported outcomes, and non-inferiority studies. Understand the challenges and opportunities in developing innovative approaches to address antimicrobial resistance. Learn about the role of regulators in shaping the future of non-traditional antibiotics and their potential impact on treating infections caused by resistant pathogens like VRE.